Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 22343491)


Cyr61 is a potential prognostic marker for prostate cancer.

Terada N, Kulkarni P, Getzenberg RH.

Asian J Androl. 2012 May;14(3):405-8. doi: 10.1038/aja.2011.149. Epub 2012 Feb 20. Review.


PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.

Jiao L, Shen D, Liu G, Jia J, Geng J, Wang H, Sun Y.

Anticancer Res. 2014 Jun;34(6):2919-25.


Cyr61: a potential therapeutic target for prostate cancer.

Lin CM, Liang CZ.

Asian J Androl. 2014 Sep-Oct;16(5):788-9. doi: 10.4103/1008-682X.128517. No abstract available.


Study identifies novel biomarker of prostate cancer reoccurrence.

Thorne J.

Bioanalysis. 2014 Mar;6(5):596. No abstract available.


Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer.

Zhang H, Wei Q, Liu R, Qi S, Liang P, Qi C, Wang A, Sheng B, Li L, Xu Y.

PLoS One. 2014 Mar 20;9(3):e91069. doi: 10.1371/journal.pone.0091069. eCollection 2014.


Prostate cancer: prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression.

Barboro P, Salvi S, Rubagotti A, Boccardo S, Spina B, Truini M, Carmignani G, Introini C, Ferrari N, Boccardo F, Balbi C.

Int J Oncol. 2014 May;44(5):1589-98. doi: 10.3892/ijo.2014.2345. Epub 2014 Mar 14.


Cyr61 expression is associated with prognosis in patients with colorectal cancer.

Jeong D, Heo S, Sung Ahn T, Lee S, Park S, Kim H, Park D, Byung Bae S, Lee SS, Soo Lee M, Kim CJ, Jun Baek M.

BMC Cancer. 2014 Mar 7;14:164. doi: 10.1186/1471-2407-14-164.


Cysteine-rich, angiogenic inducer, 61 expression in patients with ovarian epithelial carcinoma.

Lin Y, Xu T, Tian G, Cui M.

J Int Med Res. 2014 Apr;42(2):300-6. doi: 10.1177/0300060513505268. Epub 2014 Mar 4.


Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer.

Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, Xu Y.

J Exp Clin Cancer Res. 2013 Oct 16;32:77. doi: 10.1186/1756-9966-32-77.


Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease.

Hoogland AM, Verhoef EI, Roobol MJ, Schröder FH, Wildhagen MF, van der Kwast TH, Jenster G, van Leenders GJ.

Prostate. 2014 May;74(5):488-96. doi: 10.1002/pros.22768. Epub 2013 Dec 27.


The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.

Huang Y, Liu X, Wang YH, Yeh SD, Chen CL, Nelson RA, Chu P, Wilson T, Yen Y.

Urol Oncol. 2014 Jan;32(1):51.e9-19. doi: 10.1016/j.urolonc.2013.08.002.


Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression.

Saraon P, Trudel D, Kron K, Dmitromanolakis A, Trachtenberg J, Bapat B, van der Kwast T, Jarvi KA, Diamandis EP.

Prostate. 2014 Apr;74(4):372-80. doi: 10.1002/pros.22758. Epub 2013 Dec 6.


Expression and clinical significance of the nin one binding protein and p38 MAPK in prostate carcinoma.

Che JP, Li W, Yan Y, Liu M, Wang GC, Li QY, Yang B, Yao XD, Zheng JH.

Int J Clin Exp Pathol. 2013 Oct 15;6(11):2300-11. eCollection 2013.


The up-regulation of cysteine-rich protein 61 induced by transforming growth factor beta enhances osteosarcoma cell migration.

Chen J, Song Y, Yang J, Gong L, Zhao P, Zhang Y, Su H.

Mol Cell Biochem. 2013 Dec;384(1-2):269-77. doi: 10.1007/s11010-013-1807-3. Epub 2013 Sep 14.


STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma.

Ihlaseh-Catalano SM, Drigo SA, de Jesus CM, Domingues MA, Trindade Filho JC, de Camargo JL, Rogatto SR.

Histopathology. 2013 Nov;63(5):678-85. doi: 10.1111/his.12226. Epub 2013 Sep 11.


Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.

Grupp K, Höhne TS, Prien K, Hube-Magg C, Tsourlakis MC, Sirma H, Pham T, Heinzer H, Graefen M, Michl U, Simon R, Wilczak W, Izbicki J, Sauter G, Minner S, Schlomm T, Steurer S.

Exp Mol Pathol. 2013 Oct;95(2):227-34. doi: 10.1016/j.yexmp.2013.08.002. Epub 2013 Aug 12.


Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer.

Piao YR, Piao LZ, Zhu LH, Jin ZH, Dong XZ.

Asian Pac J Cancer Prev. 2013;14(6):3897-901.


Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer.

Altintas DM, Allioli N, Decaussin M, de Bernard S, Ruffion A, Samarut J, Vlaeminck-Guillem V.

PLoS One. 2013 Jun 28;8(6):e66278. doi: 10.1371/journal.pone.0066278. Print 2013.


Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.

Schubert M, Spahn M, Kneitz S, Scholz CJ, Joniau S, Stroebel P, Riedmiller H, Kneitz B.

PLoS One. 2013 Jun 14;8(6):e65064. doi: 10.1371/journal.pone.0065064. Print 2013.


Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma.

Jung K, Reszka R, Kamlage B, Bethan B, Stephan C, Lein M, Kristiansen G.

Int J Cancer. 2013 Dec 15;133(12):2914-24. doi: 10.1002/ijc.28303. Epub 2013 Jun 29.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk